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Twelve novel mutations in the SLC26A3 gene in 17 sporadic cases  



































CEINGE-Biotecnologie Avanzate scarl, Naples, 80145 Italy. 
2
Dipartimento di Medicina 
Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Naples, 
80131 Italy. 
3
Dipartimento Integrato Materno Infantile, Azienda Ospedaliero-Universitaria 
Policlinico di Modena, Modena, 41124 Italy. 
4
Dipartimento di Scienze Pediatriche Mediche 
e Chirurgiche, Università degli Studi di Messina, Messina, 98125 Italy. 
5
Dipartimento di 
Scienze Mediche Traslazionali, Università degli Studi di Napoli Federico II, Naples, 80131 
Italy. 
 
Corresponding author: Giuseppe Castaldo, MD, PhD. CEINGE-Biotecnologie avanzate, 
via G. Salvatore 486, I-80145, Naples, Italy. Tel. +39.081.3737860, Fax: +39.081.3737808, 
e-mail: giuseppe.castaldo@unina.it 
 
Conflict of interest: the authors declare no conflict of interest. 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
Acknowledgements: Grants from Regione Campania, DGRC 1901/09 and AIFA 
MRAR08W002 are gratefully acknowledged. 
 
Word count: 2698 
Number of figures:1 
Number of tables:1  
Supplemental Digital Content: 1 
 
 
Supplemental digital content is available for this article. Direct URL citations appear in the 
printed text, and links to the digital files are provided in the HTML text of this article on 
the journal’s Web site (www.jpgn.org). 
 
Abstract  
Objectives: we aimed to improve the knowledge of pathogenic mutations in sporadic cases 
of congenital chloride diarrhea (CCD) and to emphasize the importance of functional 
studies to define the effect of novel mutations.  
Methods: all SLC26A3 coding regions were sequenced in 17 sporadic CCD patients. 
Moreover, the minigene system was used to analyse the effect of two novel splicing 
mutations.  
Results: we defined the SLC26A3 genotype of all 17 CDD patients and we identified 
twelve novel mutations. Using the minigene system we confirmed the in silico prediction of 
a complete disruption of splicing pattern caused by two of these novel mutations: the 
c.971+3_971+4delAA and c.735+4_c.735+7delAGTA. Moreover, several prediction tools 
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and a structure-function prediction defined the pathogenic role of six novel missense 
mutations. 
Conclusion: we confirm the molecular heterogeneity of sporadic CDD adding twelve novel 
mutations to the list of known pathogenic mutations. Moreover, we underline the 
importance, for laboratories that offer molecular diagnosis and genetic counseling, to 
perform fast functional analysis of novel mutations.  
 
Key words: Chloride Losing Diarrhea, SLC26A3, DRA, Mutations, Genotype, Splicing 
effect
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Non standard abbreviations: CDD: congenital chloride diarrhea; SLC26A3: member 3 
of solute carrier family 26; US: ultrasonography; 
 
What is known 
 About 200 cases of sporadic congenital chloride diarrhea (CCD) have been 
described so far 
 About 80 SLC26A3 mutations have been found in CCD patients 
 Some mutations may affect the splicing process 
 
What is new 
 We describe 17 novel cases of sporadic CCD 
 We describe 12 novel SLC26A3 mutations 
 We describe the use of the minigene assay to define the splicing effect of two novel 
mutations 
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Introduction 
Congenital Chloride Diarrhea or Chloride Losing Diarrhea (CCD, OMIM #214700) 
is a severe autosomal recessive disease characterized by watery diarrhea with a high fecal 
chloride loss and metabolic alkalosis. It is characterized by maternal polyhydramnios, 
dilated fetal bowel loops and preterm birth. After birth, profuse watery diarrhea usually 
causes electrolyte imbalance with hypochloremic metabolic alkalosis or hyponatremia and 
life threatening dehydration (1-3). The disease is lethal if undiagnosed or untreated, but an 
early diagnosis and oral NaCl/KCl replacement may improve growth and the outcome of 
the disease (4).  
Mutation analysis is crucial for the diagnosis of such disease (5, 6) that may be 
misdiagnosed (7-9) or confounded with a myriad of other causes of chronic diarrhea 
including other genetic disorders(3, 10). Furthermore, molecular diagnosis may be used for 
prenatal diagnosis in high-risk couples (11, 12). Finally, the SLC26A3 genotype influences 
the responsiveness to oral butyrate therapy(13-15). CCD is caused by mutations in the 







-independent, exchanger (16). In ethnic groups where the disease 
is more frequent for founder effect, there is a single mutation (17): in Finns (incidence: 
1:20-30.000), the p.V317del mutation affects up to 90% of CCD alleles; in Saudi Arabia 
(incidence: 1:5.000) and Kuwait (incidence: 1:3.200), p.G187X affects more than 90% of 
altered chromosomes; and in Poland (incidence: 1:200.000) 50% of the CCD alleles carry 
the I675-676ins mutation (official nomenclature: c.2025insATC). Differently, a large 
genetic heterogeneity has been reported in about 200 CCD sporadic patients from other 
ethnic groups and causing mutations spread all over the disease gene (6, 18, 19). However, 
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the sequencing of the whole coding regions of the SLC26A3 gene is required for molecular 
analysis, but frequently novel mutations are identified that may be difficult to classify as 
pathogenic variant (6). Thus, data on novel mutations found in well-defined cases of CCD 
are contributory to improve the knowledge of pathogenic mutations. Moreover, functional 
studies play a key role to define the effect of novel mutations. 
We analyzed by sequencing the whole coding region of the SLC26A3 gene in 17 
sporadic cases of CCD (three of which had an affected sibling). Finally, using the in vitro 
functional minigene assay, we confirmed the pathogenic effect of two of these novel 
mutations. 
 
Subjects and methods 
Subjects 
The Pediatric Gastroenterology Unit at the University of Naples Federico II is an 
International Reference Center for patients with CCD and other forms of congenital 
diarrheal diseases (3, 10). From 2005 to 2014, 50 cases of suspected CCD were referred to 
the Center, and a definitive diagnosis was obtained in 38 patients. Among these, 18 were of 
arabian origin and were homozygous for the G187X mutation (16) and 20 were sporadic 
cases of different ethnicity. Of these 20 cases of CCD, 3 included two affected siblings. 
Finally, we describe the SLC26A3 (NM_000111) genotype of 17 sporadic, unrelated cases 
of CDD, 7 of which are enrolled in the study on butyrate treatment (14). 
All the participants (guardians in the case of minors) provided written informed 
consent to anonymously use a DNA sample and clinical data for research purposes. 
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Molecular analysis of SCL26A3 gene 
Molecular analysis was performed in the laboratory of CEINGE-Advanced 
Biotechnologies that acts as reference center for molecular diagnosis of inherited diseases 
in Campania region (about 6 million of inhabitants), located in southern Italy. DNA was 
extracted from an EDTA blood sample with the Nucleon BACC2 kit (GE Healthcare 
Europe GmbH, Milan, Italy). The touchdown PCR protocol that enables co-amplification of 
all exons under the same PCR conditions (primers and conditions are available on request). 
Sequencing analysis was carried out on both strands with an automated procedure (3100 
Genetic Analyzer, Life Technologies, Monza, Italy). All PCR fragments were sequenced 
with the primers used for PCR. Novel mutations were analyzed in 100 unrelated healthy 
control subjects whose DNA is available c/o our biological bank by gene sequencing or by 
DHPLC(20). Procedures are available on request. 
In silico prediction analysis 
The genomic sequence of interest, wild-type and mutated form, were submitted for 
splice-site prediction to the Alamut v2.0 and NetGene2 
(http://www.cbs.dtu.dk/services/NetGene2) biosoftwares (21, 22). 
Databases 
The identified c.971+3_971+4delAA and c.735+4_735+7delAGTA mutations have been 
deposited in the Leiden Open Variation Database (LOVD) at 
http://databases.lovd.nl/shared/individuals/00018561. 
Minigene Construct 
To study the effect of the genetic variants on splicing pattern, we amplified a region 
of 1.2 kb of the SLC26A3 gene containing the exon 7 and 8 to study the 
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c.971+3_971+4delAA mutation (Case #2) and a region of 0.6 kb containing the exon 6 for 
the c.735+4_735+7delAGTA mutation (Case #3). The PCR was performed directly from 
genomic DNA of heterozygous subject, using the following primers: 
- Case #2:  
Fw: 5’-CATTCAGGTACCTCCATCGCTACTC-3’  
Rev: 3’-CATTCAGGTACCCTGGCCTTACTTTGC-5’.  
- Case #3: 
Fw: 5’-AGCACGGTACCTGCAAATAAGCCTGTTACTTCTTG-3’ 
Rev: 5’ CAGCTATGGTACCTGATCTCGTGATCCGC-3’. 
These primers contained the KpnI restriction sites to cut the PCR products by KpnI 
restriction enzyme and to clone them into the pMGene vector (23) previously digested with 
KpnI and dephosphorylated. All clones were sequenced to confirm the insert sequence. 
Cell cultures 
HeLa cells (ATCC – CCL-2) were maintained in Dulbecco's Minimum Essential 
Medium (ATCC 30-2003) with 10% heat-inactivated fetal bovine serum (GE Healthcare 
Europe GmbH); T84 colon cell lines (ATCC – CCL-248) were maintained in a 1:1 mixture 
of Ham's F12 medium and Dulbecco's modified Eagle's medium with 2.5 mM L-glutamine, 
5% heat-inactivated fetal bovine serum, cultures were maintained in 5% (v/v) CO2 
humidified atmosphere at 37°C.  
Minigene Expression and Transcripts Analysis 
HeLa and T84 cells seeded in 60-mm dishes were transfected with 5 µg of pMGene 
constructs by lipofectamine reagent (Life Technologies). Transfection medium was 
replaced with fresh medium 6h after the transfection. 24 hours after transfection, cells were 
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collected and total RNA was extracted using the MasterPure Complete DNA and RNA 
Purification Kit (Epicentre, Madison, WI, USA), 1 µg of total RNA was reverse transcribed 
using M-MLV Reverse Transcriptase (Life Technologies). After total RNA retro-
transcription, 1/20 of cDNA was PCR amplified using the following primers:  
RT-Mgene-For: 5’-CACATGGTCCTGCTGGAGTTC-3’  
RT-Mgene-Rev: 5’-CCTGCACTGGTGGGGTGAATTC-3’.  
The PCR products were then separated on a 1,5% agarose gel, and individual bands 
were excised and sequenced using the specific primers. 
 
Results 
The SLC26A3 genotype of the 17 CCD patients is shown in (Supplemental Digital 
Content 1, Table, http://links.lww.com/MPG/A788): 11/17 (64.7%) patients were 
homozygous for a SLC26A3 mutation, while 6/17 (35.3%) patients were compound 
heterozygous for two mutations. In the 11 homozygous patients with CDD we tested both 
parents (that resulted invariably heterozygous) to exclude the possibility that a large gene 
deletion would cause a false homozygous mutation result; in 3 cases; in which the parents 
were not available for the analysis, we excluded the presence of a large deletion by 
quantitative RT-PCR analysis of the involved exon. Similarly, for all 6 compound 
heterozygous patients we studied at least one parent to confirm that the two mutations 
found in the patients were in trans. Finally, we identified mutations in 34/34 alleles 
(100%). In particular, we found 21 different mutations: 9 missense, 3 nonsense, 2 single 
nucleotide deletion causing frameshift, 2 splicing intronic point mutation, 1 codon 
duplication, 1 large deletion, 1 codon deletion, 1 intronic four nucleotides deletion and 1 
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intronic two nucleotides deletion, both these latter causing a splicing effect. Among the 21 
mutations, 12 (57.1.%) were novel (6 missense, 3 deletions, 2 frameshift, 1 nonsense).  
All the mutations were identified by gene sequencing with the exception of the large 
deletion (case #1 – Supplemental Digital Content 1, Table, 
http://links.lww.com/MPG/A788). In fact, after the gene sequencing, no gene variants were 
found in such patient, but exon 18 lack to amplify. To exclude mutations in the primer(s) 
site, we used a more external set of primers and again, exon 18 did not amplify. Re-
amplification using the long-PCR procedure revealed an homozygous large deletion; the 
heterozygous deletion was present in both parents. The walking primer analysis revealed 
the first breakpoint in position c.2008-151 and the second breakpoint in position 
c.2061+1546. 
We functionally analysed two novel intronic mutations, i.e., the 
c.971+3_971+4delAA and the c.735+4_c.735+7delAGTA. Both mutations were found in 
homozygous patients. First of all, we analysed in silico the putative effect of both 
mutations, predicting a complete disruption of the physiological splicing pattern. Then, we 
analyzed in vitro the splicing pattern using the minigene system assay. Briefly, the exons of 
interest were cloned in the minigene construct (Figure 1A) and transfected in Hela and T84 
cells. The RT-PCR analysis on total RNA extracted from the transfected cells confirmed 
the in silico prediction. Indeed, in both cases, the RT-PCR analysis revealed a complete 
disappearance of the wild-type band (Figure 1B-1C). In particular, the sequencing analysis 
of each electrophoretic separated band revealed the following data: for the 
c.971+3_971+4delAA mutation, we obtained two alternative bands: the upper one due to 
the skipping of exon 8 and the lower one due to the skipping of both exon 7 and 8. For the 
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c.735+4_c.735+7delAGTA mutation, the mutated construct resulted in a lower band 
corresponding to the skipping of exon 6. We confirmed the same splicing aberration pattern 
in T84 cell line, that expresses a splicing machinery of colon cells and represents a more 
physiological context for SLC26A3 gene expression. 
The six novel missense mutations (Table 1) were not found in 200 alleles from 
healthy subjects. Furthermore, the novel mutations were not reported in the 1000 genomes 
browser (http://browser.1000genomes.org) and in the Exome Variant Server 
(http://evs.gs.washington.edu/EVS/). Among the missense mutation: the p.S394I involves 
the random coil/ -helical border changing the neutral polar serine into the apolar 
isoleucine aminoacid; both the prediction tools indicated a high risk of pathogenicity. The 
mutation was found in two CCD siblings (in trans with the p.Q48X nonsense mutation). 
Similarly, the p.S43 -helical border changing the neutral 
polar serine into the apolar proline aminoacid and was found in a CCD patient that had a 
frameshift mutation on the other allele; both the prediction tools indicated a high risk of 
pathogenicity for the S438P. The A547E mutation involves the STAS domain and both the 
prediction tools indicated a high risk of pathogenicity. A missense mutations that abolish 
the protein function in an adjacent codon (i.e., the p.I544N) was already found in a CCD 
patient (6, 18). The A547E was found in a patient compound heterozygous for the novel 
missense Q495P mutation. Such latter causes the change of the neutral polar glutamine with 
the apolar proline aminoacid. Although the PolyPhen software predicted the mutation as a 
possibly damaging and SIFT as a tolerated mutation, it involves the same codon of the 
p.L496R mutation previously found in other CCD patients (6, 18, 19). The p.S654P 
involves the STAS domain changing the neutral polar serine into the apolar proline 
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aminoacid; the mutation was found homozygous in a CCD patient and was predicted as 
probably damaging by PolyPhen, while SIFT predicted the p.S654P as a tolerated mutation, 
but a mutation in an adjacent codon (i.e., the p.D652N) was previously reported in CCD 
patients (5, 18). Finally, the p.C508R was found in a patient that had the p.R579X nonsense 
mutation on the other allele. The mutation changes the neutral polar cysteine with the basic 
polar arginine aminoacid within the random coil/intracellular domain of the protein. The 
mutation was predicted as probably damaging by PolyPhen, while SIFT predicted the 
p.C508R as a tolerated mutation; the p.P506Q mutation that abolishes protein function in 
an adjacent codon was described in CCD patients (6, 17). Three other missense mutations 
found in our patients (i.e., the pG120S, the pP131R and the p.P129L), all reported as 
pathogenic by both the prediction tools (data not shown) had been previously found in CLD 
patients (6, 18, 19). 
 
Discussion 
Molecular analysis of the SLC26A3 gene revealed the genotype of all the 17 patients 
with CCD and confirmed the genetic heterogeneity of sporadic CCD (6, 18, 19). In fact, the 
mutations we identified spread all over the gene, which suggests that the analysis in 
sporadic CCD patients should be based on sequencing of all SCL26A3 gene coding regions, 
differently from ethnic groups where CCD is frequent and the analysis is routinely based on 
the study of a single mutation (6, 17). 
We identified several novel mutations clearly affecting the synthesis or the activity 
of the protein and thus, resulting in having a pathogenetic role. This is true for the large, 
1752-bp deletion in patient #1, that removes the whole exon 18 (55 bp) likely resulting in a 
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frameshift event (p.I670MfsX17). Similarly, the novel deletions found in patient #2 (found 
in two affected siblings) and in patient #3 are causing disease because they impair the 
splicing pattern, as we demonstrate in the present study. Indeed, phylogenetic analysis and 
in silico prediction may help to define the disease-causing effect of splicing mutations, as it 
is the case for both novel mutations, but only functional analysis permits to finally 
demonstrate such effect. In this context, the minigene assay we used represents a fast 
technique that allows, in about two-weeks, to functionally analyze mutations with a 
putative splicing effect. Noteworthy, 4/21 mutations (19%) found in the present study are 
deletions among which one was large, confirming that such type of mutation are frequently 
found in monogenic disorders, as we previously demonstrated for haemophilia A, in which 
about 19% of 217 mutations are gene deletions (24) and in cystic fibrosis in which large 
rearrangements are found in about 3% of affected alleles (25). 
Furthermore, the single nucleotide deletions observed in patients #6 and #13 (this 
latter found also in patient #14) cause a frameshift and thus, a truncated inactive protein. 
The same is true for the novel nonsense mutation found in patient #11.  
More difficult it is to define the pathogenic role of six novel missense mutations 
found in our CCD patients. Some criteria suggest their pathogenic role: i) they were absent 
from 200 normal alleles and in the 1000 genomes browser 
(http://browser.1000genomes.org) and in the Exome Variant Server 
(http://evs.gs.washington.edu/EVS/); ii) in all cases, each of the parents was heterozygous 
for one of the mutations identified in the proband; iii) no other mutations were identified in 
the SLC26A3 gene in these patients; and iv) the amino acids affected by the mutations are 
highly conserved. In detail, both novel missense mutations identified in patient #15, 
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namely, p.Q495P and p.A547E, lie within the mutation-bearing hotspots characteristic of 
most sporadic CCD cases (19). The p.Q495P mutation could affect the correct folding of 
the last but two transmembrane domain of the protein (according to the 14 transmembrane 
-helices model) (26-28) thereby altering the charge distribution. Alternatively, the 
mutation could alter the sulphate transporter family domain (19). The p.A547E mutation 
also involves the first -sheet of the “STAS-like” domain. Glutamic acid is a powerful -
sheet interrupter and probably also induces a strong charge distribution change. Indeed, 
mutations involving the STAS-like domain have been associated to the absence of residual 
activity of the protein (29, 30). Patient #16 is homozygous for the novel missense mutation 
p.S654P. The mutation involves a highly conserved amino acid belonging to the conserved 
-helix of the STAS-like domain. We suggest p.S654P is 
a disease- -sheet interrupter and 
mutations affecting amino acids within the “STAS-like” domain are very likely to be 
disease-causing. Moreover, the p.S654P involves a palindromic sequence 
(c.GACTTTTCAG -> c.GACTTTCCAG), which could be more susceptible to mutations. 
The p.S438P mutation (patient #13) involves serine 438, the last amino acid of the random 




 transmembrane helix (according to the 14 
transmembrane - -helices. 
Alternatively, the mutation could alter the sulphate transporter family domain. Also in this 
case, the mutation lies in the hotspot region (19). 
To conclude: our data confirm the high genetic heterogeneity of CCD in ethnic 
groups where the disease is sporadic. This highlights the importance to analyze the whole 
coding region by gene sequencing in patients suspected for sporadic CCD, particularly 
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when born to consanguineous parents. In case of novel, missense mutations, other 
mutations must be excluded and the novel mutation must be tested in a large number of 
unaffected chromosomes. Phylogenetic analysis and in silico prediction may help to 
confirm the disease-causing effect of novel mutations but functional analysis, here 
performed for two splicing affecting mutations, is very helpful to conclude on the 
pathogenetic effect.  
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Supplemental Digital Content 
SDC 1: SLC26A3 (NM_000111) genotype of 17 patients with CCD. The asterisk marks 
novel mutations; the double asterisk marks the cases that have an affected sib-pair with 









Copyright © ESPGHAN and NASPGHAN. All rights reserved.
Legend to the figure  
Figure 1: A. Schematic structure of the pMGene empty and of the pMGene-DRA 
constructs showing the position of the novel genetic variants. B and C. RT-PCR analysis 
of mRNA extracted from cell transfected with the indicated pMGene constructs 
(M=mutated, W=wild type). The white arrows indicate the position of the PCR products 
with a schematic view in the right side. T84 (Human lung metastase from colorectal 
carcinoma cells) and HeLa (cervical cancer cells) 
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Table 1: Possible pathogenic role of missense mutations. For each of the 6 mutations, the Table reports: i) the protein domain involved by the mutation; ii) 
the PopyPhen prediction score of pathogenicity; iii) the SIFT prediction score of pathogenicity; iv) the list of mutations previously described involving 
adjacent aminoacids.) 
 
Mutation  Mutation Domain    PolyPhen prediction  SIFT prediction Adjacent mutations 
cDNA  protein      score    score  
 
c.1181G>T* p.S394I* random coil/ -helical border  1 (probably damaging) 0 (deleterious) 
 
c.1312T>C* p.S438P* random coil/ -helical border  0.998 (probably damaging) 0 (deleterious)   
 
c.1640C>A* p.A547E* STAS domain    0.993 (probably damaging) 0 (deleterious)  I544N (6,7)  
 
c.1960T>C* p.S654P* STAS domain    0.93 (probably damaging) 0.07 (tolerated) D652N (6,7) 
 
c.1522T>C* p.C508R* random coil/intracellular domain 0.713 (possibly damaging) 0.12 (tolerated) P506Q (7,24) 
 
c.1484A>C* p.Q495P* random coil/intracellular domain 0.696 (possibly damaging) 0.09 (tolerated) L496R (6,7,19) 
 
 
 
 
